petosemtamab
merus
['head and neck', 'petosemtamab']
petosemtamab can produce durable responses in patients with advanced head and neck squamous cell carcinoma, a phase 1/2 study presented at aacr 2023 suggests. #aacr23 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.